Historical review of cervical arthroplasty

HOANG LE, M.D., ISSADA THONGTRANGAN, M.D., AND DANIEL H. KIM, M.D.

Department of Neurosurgery, Stanford University Medical Center, Stanford, California

Early attempts at spinal arthroplasty in the 1950s yielded limited success. A revival of this procedure occurred in the 1980s and became a realistic treatment option in the 1990s. Both lumbar and cervical arthroplasties have been introduced in the US since 2000 for randomized, prospective studies in accordance with the Food and Drug Administration (FDA) investigational device exemption provisions. In June 2004 the first lumbar arthroplasty device was approved by the FDA for use in the US. It is likely that cervical arthroplasty will soon follow and may be available for widespread use as early as 2006. In this paper the authors review the historical development of cervical arthroplasty.

KEY WORDS • spinal arthroplasty • cervical arthroplasty • disc replacement • degenerative disc disease • historical review

There is great enthusiasm in the US with regard to the impending approval by the FDA of a cervical arthroplasty device. The concept of arthrodesis was applied to many severe joint disorders until there was widespread acceptance of hip and knee arthroplasty techniques. Nevertheless, whereas arthrodesis of the hip and knee produces severe loss of function, the loss of motion in an intervertebral segment is well tolerated. Why, then, is cervical arthroplasty so appealing, given the excellent clinical outcomes of current arthrodesis techniques?

OVERVIEW

Concerns for the possibility of acceleration of adjacent-segment disease after fusion have been growing. Furthermore, there are other drawbacks to fusion, including the alteration of spinal biomechanics, graft and hardware complications, and harvest site pain. In addition, it must be realized that neural decompression, not fusion, remains the primary indication and goal of anterior cervical surgery. Cervical arthroplasty provides the opportunity to preserve motion after neural decompression while providing stability. In the following sections, we will discuss key factors that led to the development of cervical arthroplasty.

Adjacent-Segment Disease

For treatment of cervical disc disease, the ACDF procedure has been well accepted since the 1950s. Although these surgical procedures are very effective in alleviating symptoms and improving neurological outcomes, the adverse long-term effects of interbody fusion have been the subject of considerable debate. Long-term follow-up studies conducted after anterior cervical fusion have shown that up to 92% of patients demonstrate adjacent-level degeneration on radiographs. Biomechanical studies have been performed to evaluate intradiscal pressure and dynamic stability at disc segments adjacent to the fusion. In a human cadaveric model, investigators in several studies have demonstrated increased intradiscal pressure recordings in adjacent disc segments after fusion. Clinical symptoms, however, have not correlated well with the severity of degenerative changes seen on x-ray films. Biomechanical studies in which dynamic radiography was used have also shown increased motion at adjacent segments above and below the level of cervical fusion, and this may be a factor associated with deterioration after anterior cervical fusion. Matsunaga, et al., developed a mathematical model to evaluate the shear strain of the adjacent disc segments after cervical fusion. For two- or three-level ACDFs, shear strain was increased by 20% after 1 year and 64% of adjacent discs that showed an abnormally high strain before the ACDF procedure herniated after the fusion in their follow-up study. A validated finite element analysis has also demonstrated increased internal stress at adjacent segments. Fuller and colleagues, however, were unable to demonstrate adjacent-segment hypermobility after fusion in a human cadaveric model by using stereophotogrammetry. Nevertheless, the older age of the harvested cadaveric specimens as well as the inherent nature of rigor mortis may have counteracted any potential for adjacent segment hypermobility.

Clinically, long-term deterioration after ACDF has been
documented in several studies. Hilibrand, et al.,6 studied 374 patients who had undergone anterior cervical fusion and reported that adjacent-segment degeneration with new radiculopathic symptoms occurred in 2.9% of them per year, with a cumulative rate of 25% in a 10-year period. Two thirds of these patients required additional cervical fusion surgeries. Ironically, the incidence of adjacent-segment degeneration was lower in patients with multilevel anterior cervical fusions.

After a follow-up period of almost 10 years, Katsuura, et al.,40 reported radiographically confirmed changes consisting of adjacent-segment degeneration after anterior cervical fusion in 50% of patients, with 19% requiring additional cervical surgeries. Gore and Sepic,30 with a mean follow-up duration of 21 years after the initial ACDF, reported that 16% of their patients required additional cervical surgeries for symptomatic adjacent segment degeneration. In other long-term studies a repeated operation rate of 6 to 7% has been reported for adjacent-segment disease after ACDF.7,26,46 This is in contrast with the repeated operation rate of 1% for posterior discectomy procedures in which segmental motion is preserved.39,66

The natural progression of disc degeneration seems undeniable; in 34% of asymptomatic patients with normal findings on baseline cervical x-ray films, radiographically confirmed DDD had developed when they were reevaluated 10 years later.28 In the same study, 97% of patients with preexisting disc degeneration showed progression 10 years later. This raises an interesting question in regard to adjacent-segment disease: does the development of this disorder after ACDF represent the natural progression of DDD or does it represent an accelerated degenerative process influenced by the biomechanical effect of fusion? The influence of the latter is supported by documentation of adjacent-segment disease in the pediatric population. Long-term follow-up review of pediatric patients who required anterior cervical fusion for fractures and dislocation revealed a high rate of adjacent-segment disease.72 Furthermore, in cases of Klippel–Feil syndrome, in which congenital cervical fusion is known to occur, magnetic resonance imaging studies revealed signal intensities consistent with DDD in adjacent segments in all patients.72

The available literature indicates that adjacent-segment disease is affected by both natural history and the biomechanical stress of fusion. It is clear that as many as one of every five patients undergoing a cervical fusion will require another such procedure during a long-term follow-up period. Despite the immediate gratification of good results following the ACDF procedure for the treatment of cervical disc disease, long-term clinical deterioration leaves room for improvement. The concern that spinal fusion surgery may be a contributing factor to accelerated DDD has spurred an interest in motion preservation surgery. The surgical evolution from arthrodesis to arthroplasty is not new. The overwhelming success of hip arthroplasty over arthrodesis provides a leading example for spinal arthroplasty. We will discuss this in the following section.

Historical Progression From Arthrodesis to Arthroplasty for Hip Surgery

Traditionally, the generation of pain was attributable to the motion of a degenerative joint, and thus the treatment of pain can be effectively addressed with joint arthrodesis. Before the 1960s, hip fusion was considered the gold standard of treatment for severe osteoarthritis and hip dysplasia. This was very effective for treating pain but left patients with severe disabilities. Several authors have reported satisfactory long-term function after hip arthrodesis, with most patients gainfully employed and able to walk more than 1 mile. Unfortunately, 32% experienced difficulties with sexual activity, and more than 70% graded their activity as below average for their age group, particularly the female patients.69 Another study also showed positional disabilities, including difficulty kneeling or sitting, difficulty putting on and taking off socks, and difficulty climbing stairs.53,69 These patients also experienced significant gait changes, with significant limb-length discrepancy.29,30 Biomechanical data reported by several authors11,34,70 also revealed increased loading in the ipsilateral knee and lower lumbar region, which can accelerate degenerative changes in those regions.

Dissatisfaction with the consequences of hip arthrodesis led to the development of total hip arthroplasty. During this procedure, both femoral and acetabular bearing surfaces are surgically replaced with metallic, polymeric, and/or ceramic components. Throughout the 20th century, many different combinations of these materials were explored as bearing surfaces for total hip arthroplasty.

Metal-on-metal total hip replacement devices were first implanted by Wiles7 in the 1930s and further developed in the 1950s and 1960s by pioneering surgeons like McKee53 and Ring. In 1958, Charnley introduced a “low-friction arthroplasty” based on the principle of a metallic femoral component articulating against a polymeric acetabular component. In 1970, Boutin, et al. developed the first ceramic-on-ceramic total hip replacement device. Charnley’s hard-on-soft bearing concept eventually dominated the other hard-on-hard bearing alternatives based on long-term outcomes. This hard-on-soft bearing concept has influenced the design of other total joint arthroplasty devices as well as total disc arthroplasty.

Today the most widely accepted bearing couple consists of a femoral head fabricated from a cobalt chromium molybdenum alloy articulating against a polymeric component fabricated from UHMWPE. The use of the cobalt chromium molybdenum UHMWPE–bearing couple has provided consistent results in total hip arthroplasties performed worldwide for the past four decades. Nevertheless, polyethylene wear and periprosthetic osteolysis are major obstacles limiting the longevity of these reconstructions. It is now well established that particulate debris generated from the articulating surfaces initiates a cascade of adverse tissue responses leading to osteolysis and in certain cases loosening of the components.66

Recently, researchers have attempted to improve devices currently in use and to design alternative bearing surfaces to reduce wear and possibly osteolysis. Most recently, in the late 1990s, numerous researchers at centers around the world confirmed that cross-linking of UHMWPE, whether by radiation, peroxide, or silane chemistry, can substantially improve the wear performance of the material in hip joint simulators.51–55 With hip arthroplasty as a successful treatment superseding hip arthrodesis, the
Historical review of cervical arthroplasty

progression from spinal arthrodesis to arthroplasty appears to be the next logical step.

**Historical Aspects of Cervical Disc Arthroplasty**

Since the 1950s, and especially within the last 10 years, there have been many patented implants designed for restoration of the viscoelastic function as well as preservation of motion in the intervertebral space. The majority of these implant designs, however, focused on disc replacement in the lumbar spine, whereas a few focused on the cervical spine. Despite the many implant designs, very few have reached the stage of animal studies and fewer have progressed to human clinical trials.

Several factors have influenced the slow progress with spinal arthroplasty. In contrast to knee and hip joints, in which ligamentous structures are of paramount importance in the maintenance of joint stability, the disc itself contributes a significant portion to spinal stability. Disc arthroplasty must take into consideration the additional factor of restoring balance to the facet joints and resetting the instantaneous axis of rotation to the posterior aspect of the disc space. The development of biomaterials for total disc replacement must take into consideration the high demands of a lifetime of strain imparted to the implant. The optimal life span of a spinal implant is 30 to 50 years. During this time the device will undergo between 10 and 30 million cycles; the spine undergoes approximately 100 million flexion cycles during a lifetime. Furthermore, prosthetic wear and the resulting debris, with its associated inflammatory reaction as seen in hip and knee arthroplasty may be a potential source of long-term failure for spinal arthroplasty. To date, however, a significant inflammatory reaction has not been noted for spinal arthroplasty devices.

Early attempts at cervical arthroplasty were met with failure. The first implantation of a cervical arthroplasty device in a human was described by Fernström in 1966. He used an intracorporal endoprosthesis shaped like a metal ball bearing, which he inserted into the disc space of both lumbar and cervical areas. A total of 191 prostheses were implanted in 125 patients. The cervical prostheses were 6 to 10 mm in diameter and replaced 13 cervical discs in eight patients. Reitz and Joubert, from South Africa, also reported the use of 75 Fernström cervical prostheses in 32 patients for the treatment of intractable headaches and cervicobrachialgia. Despite these pioneering attempts, Fernström himself admitted poor results. In the vast majority of patients followed for up to 7 years postoperatively, the spherical endoprosthesis created segmental hypermobility with a predisposition to subsidence and migration into the superior endplate. The placement of these devices has subsequently been abandoned in favor of cervical arthrodesis.

In the 1980s there was a resurgence of interest in spinal arthroplasty, specifically lumbar arthroplasty. The SB Charité prosthesis was designed in 1982 and first implanted in 1984. Problems with migration and fatigue fractures led to abandonment of the first two generations of this device. The Link SB Charité III, now in its third generation, became commercially available in 1987 and is currently the most widely implanted total disc replacement system, with more than 5000 implantations worldwide.

In studies conducted with several years of follow up, good outcomes have been reported in more than 70% of patients. A recent report on 60 prospectively randomized patients (41 with SB Charité and 19 with BAK cages) treated in a US center with a follow-up duration of between 1 and 3 years has shown a significant reduction in Oswestry Disability Index scores. Good results in more than 70% of patients with a clinical follow-up duration of 10 years after implantation of the SB Charité device have been published, along with reports of complications.

The Acroflex lumbar disc was also introduced in the 1980s. In one study it was implanted into six patients, yielding fair to poor outcomes. Concerns about the carcinogenic potential of the rubber as well as failure of the rubber component on subsequent testing have caused the withdrawal of this device from use.

In 1989, another popular disc replacement device emerged: the ProDisc. It is a metal-on-metal design and has yielded favorable long-term outcomes. Marnay published good and excellent outcomes in more than 70% of patients after follow-up periods of between 7 and 11 years, and in 1999 the ProDisc II featuring design improvements was introduced. Other authors have also reported favorable outcomes with use of the ProDisc after short-term follow up.

So far, all the spinal arthroplasty devices in use, only the SB Charité and the ProDisc have more than 5 years of clinical follow up. Both have been used in Europe for more than a decade despite the lack of long-term prospective randomized clinical trials. In the US, prospective multicenter, randomized clinical trials were initiated in 2000 for the SB Charité and in 2001 for the ProDisc. The SB Charité was approved for use in the US by the FDA in June 2004.

With the reported success of lumbar arthroplasty devices, renewed enthusiasm has emerged for the prospects of a cervical arthroplasty device. In 1989, the Department of Medical Engineering at Frenchay Hospital, Bristol, United Kingdom, began the initial design process for an artificial cervical joint. Several prototypes were created before clinical trials were initiated in 1991. The initial design was a two-piece, stainless steel, metal-on-metal, ball-in-socket configuration with anchoring screws placed anteriorly (Fig. 1). The results of the first human trial in which this cervical prosthesis (called the Cummins–Bris-
tol artificial cervical joint) was used were reported in 1998. Between 1991 and 1996, 22 Cummins joints were placed in 20 patients, with follow-up durations ranging from 3 to 65 months (mean 2.4 years).

Results for 18 patients were available for review in 1996, and 16 of these individuals demonstrated continued joint motion of 5° in flexion and extension. Overdistraction of the disc space and separation of the facet joint accounted for the lack of motion in the remaining cases. Fusion of the interspace did not occur in any patient and adjacent segment degeneration was not observed.

Complications occurred, however, in a significant number of cases. In the first five patients, a single anterior anchoring screw was placed: three patients had partial screw pullout, one had a broken screw, and one joint was subluxed. Subsequently, the technique was modified to include two anchoring screws per device component. Despite this, two cases of partial screw pullout (one broken screw and one joint subluxation) were encountered. Surgical removal of hardware in the latter case revealed the problem to be a manufacturing error; in addition, wear debris was not encountered. Screw complications were attributed to poor screw placement and the use of a uniform-sized joint. Dysphagia also developed in all patients (it was persistent in four) and was attributed to the high profile of the anterior limbs of the joint.

Based on the initial experience with the Cummins artificial cervical joint, a second-generation design was implemented to allow more physiological cervical motion that would be restrained by that of the facet joints and the surrounding tissues. The new Frenchay cervical disc replaced the lower component of the Cummins joint, which initially was a hemispherical cup, with a shallow ellipsoid saucer (Fig. 2). Freedom of translation and rotation was increased. Also, the upper vertebral component was allowed passively to determine its own axis of rotation so that physiological motion coupled with the facet joint and adjacent vertebral segments could be optimized. In addition, the screw locking mechanism was redesigned and the device was made less bulky.

The results of a 2-year pilot study of the new Frenchay artificial cervical joint were published in 2002. Fifteen patients who were particularly prone to adjacent-segment degeneration were enrolled in the study. At 2 years post-implantation, cervical motion across the implanted site was preserved in all patients except one. No settling or dislocation of the device was noted. Despite screw breakage in two of 60 instances, no screw backout was noted. Four patients experienced neck pain on full extension and one of them eventually required removal of the device. The joint in question was noted to be loose, with the surrounding fibrous tissue devoid of inflammation or wear debris. The authors attributed the device failure to excessive bone removal at the time of surgery and transference of load sharing to the facet joint.

In a prospective nonrandomized fashion, Wigfield and
coworkers also compared adjacent-segment motion after implantation of the Frenchay disc with a one-level arthrodesis. In the group undergoing fusion a significant increase in adjacent-level movement (mean 9°) was demonstrated based on angular measurements at the 12-month follow-up visit compared with the group of patients in whom the Frenchay joint was placed. The fusion group experienced increases of their adjacent segment motion by 5% at 6 months and 15% at 1 year. Subgroup analysis revealed that the increase in movement occurred predominantly at the disc space that was preoperatively regarded as normal. Overall adjacent-level movement for the group that received the Frenchay device was minimally affected. Similar findings of motion preservation and minimal effects on adjacent-segment motion were also noted earlier in biomechanical studies conducted by other authors.18

In theory, the decrease in adjacent-segment motion seen with the use of an artificial joint compared with that associated with fusion should reduce the incidence of adjacent-segment disease. This remains to be firmly demonstrated in future long-term studies.

In August 2000 the first prospective, randomized trial comparing cervical arthroplasty with iliac crest autograft fusion by using the Frenchay disc (now called Prestige) was initiated at multiple centers in Australia, Europe, and the United Kingdom. Preliminary results presented at the 18th Annual Meeting of the North American Spine Society in October 2003 reportedly demonstrated favorable outcomes in the arthroplasty group, with preservation of motion and lack of progression in adjacent-segment disease. A randomized, prospective US investigational device exemption study involving the Prestige disc was initiated in 2002 and is ongoing. This product may gain FDA approval for US markets by 2006.

With the reported success of the modified Bristol discs, several other artificial cervical discs have reached the clinical testing stage. In 2001, Pointillart, an orthopedic surgeon, reported the use of a titanium cervical arthroplasty device fashioned according to the design of the unipolar hip replacements used for treating hip fractures. The device consisted of a carbon sliding surface at the cephalad aspect of the prosthesis and a titanium base secured by two screws to the caudal vertebral body (Fig. 3), and it was implanted in 10 patients between 1998 and 1999. Unfortunately, mobility was not maintained in eight patients (five experienced circumferential fusion, in two the vertebra fused posterior to the device, and one had bridging fusion anteriorly). In the two patients who suffered persistent mobility, persistent neck pain was also noted. Further use of this device has not been documented.

In contrast to the metal-on-metal design of the Bristol disc, a metal-on-plastic design called the Bryan disc emerged in the late 1990s (Fig. 4). Named after its American inventor, Vincent Bryan, the disc consists of a polyurethane core that articulates between two titanium alloy shells that include convex porous surfaces for bone ingrowth. The device is rotationally unconstrained, allows for 11° of motion in flexion, extension, and lateral bending, 2 mm of translation, is coupled to the surrounding soft tissues, and allows for shock absorption. In vivo testing in chimpanzees and goats demonstrated motion preservation, device safety, ingrowth of bone into the prosthesis shell, and no inflammatory response in the surrounding tissues.9

Clinical trials in which the Bryan disc was used were initiated in January 2000 for the treatment of a single cervical disc level. In January 2001 a second arm of the study was initiated in which the Bryan disc was evaluated for the treatment of two adjacent cervical levels. Preliminary outcomes of the European prospective multicenter trial in which the Bryan disc was used for single-level cervical disc disease were published by Goffin and coworkers in 2002. The clinical success rate was 86% in 60 patients at 6 months and 90% in 30 patients at 1 year, both of which exceeded the targeted rate of 85%. Motion was preserved in all patients, with no evidence of device migration. In 2003, a follow-up report presented intermediate results from the multicenter single-level Bryan disc trial and also preliminary data from the bilevel arthroplasty trial. In the single-level group, 100 patients reached the 1-year time point and 51 reached the 2-year mark. Success rates at 6 months, 1 year, and 2 years were 90, 86, and 90%, respectively. The bilevel group included 43 patients with 1-year data and 29 with 2-year data. The success rate for this group was 82% at 6 months and 96% at 1 year. Motion was maintained in both surgical groups, averaging more than 7° per level for the range of flexion and extension at the 1-year evaluation. No device failure or subsidence was noted in any patient.

Australian prospective trials of the Bryan disc have been ongoing since 2001. A randomized, prospective US investigational device exemption trial of the Bryan disc was also initiated in May 2002. Currently, in excess of 2000 Bryan discs have been implanted in patients in more than 17 countries outside the US since its approval for use in those countries in 2002. As yet, no significant complications associated with this device have been reported. Paravertebral ossifications noted in approximately 30% of patients have responded to early treatment with a 2-week course of nonsteroidal antiinflammatory drugs and have not affected overall clinical outcomes (Fig. 5).9

Along the same lines as the metal-on-plastic concept, the PCM artificial disc was developed recently with two different designs to address the integrity of the PLL after cervical decompression (Fig. 6). Rather than using a polyurethane core as in the Bryan disc, the PCM disc consists...
of the traditional UHMWPE compound found in hip and knee arthroplasties. It is structured for load bearing rather than being a ball-in-socket design. The porous coated component was modeled after the ingrowth capabilities of the titanium- and carbon-coated SB Charité discs. The low-profile PCM disc design is favored in situations in which the PLL is preserved, whereas the fixed PCM disc design with anchoring screws is preferred in situations in which the PLL is removed. Biomechanical studies have revealed the destabilizing effect of resecting the PLL with anterior discectomy in a cadaveric model. Initial animal testing with the PCM disc in goats followed for 6 months revealed stability of the construct with no evidence of particulate debris and porous bone ingrowth. At the 19th annual meeting of the Cervical Spine Research Society in June 2003, preliminary clinical outcomes in 20 patients in whom the PCM disc was used were reported. Odom criteria revealed good and excellent outcomes in 95% of patients. Clinical trials with the PCM disc are expected to begin soon in the US. This device may be available to the US market by 2008.

With the success of the lumbar ProDisc device, a simi-
lar construct for cervical arthroplasty was designed. The ProDisc-C, as it is called, is also a metal polyethylene ball-in-socket design with two metal fins (Fig. 7). A multicenter randomized prospective clinical trial in the US with this device is currently ongoing. Other cervical arthroplasty devices in the midst of preclinical trials are actively being developed and tested and will likely emerge in the coming years (Fig. 8). With the recent FDA approval of the first lumbar arthroplasty device in the US, it is likely that cervical arthroplasty will soon follow and can be available to US markets as early as 2006.

CONCLUSIONS

The historic progression of cervical arthroplasty is based on the clinical success encountered with hip, knee, and subsequently lumbar arthroplasties. Despite the positive short-term outcomes with cervical arthrodesis, up to 25% of patients who undergo ACDF will require another surgery within 10 years, primarily for adjacent-segment disease. Can cervical arthroplasty prevent or reduce the incidence of adjacent-segment disease? We will soon find out. Regardless, preserving and restoring natural motion to the cervical spine is intuitively desirable in the treatment of cervical disc disease. If primary clinical outcomes from the use of cervical arthroplasty can match or surpass those of cervical arthrodesis, a new treatment standard for cervical disc disease will have emerged.

References


43. Kulkarni V, Rajeshkhar V, Raghuram L: Accelerated spondylotic changes adjacent to the fused segment following central cervical corpectomy: magnetic resonance imaging study evidence. J Neurosurg (Spine 1) 100:2–6, 2004


Historical review of cervical arthroplasty


Manuscript received June 15, 2004. Accepted in final form July 26, 2004.

Address reprint requests to: Daniel H. Kim, M.D., Department of Neurosurgery, Stanford University Medical Center, Room R-201, Edwards Building, 300 Pasteur Drive, Stanford, California 94305-5327. email: neurokim@stanford.edu.